专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130131321A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY 审中-公开
标题翻译：通过亲和色谱法进行抗体和Fc融合蛋白纯化的配体
公开(公告)号：US20130131321A1
公开(公告)日：2013-05-23
申请号：US13813860
申请日：2011-08-03
申请人： Holger Bittermann , Klaus Burkert , Marc Arnold , Oliver Keil , Thomas Neumann , Inge Ott , Kristina Schmidt , Daniel Schwizer , Renate Sekul
发明人： Holger Bittermann , Klaus Burkert , Marc Arnold , Oliver Keil , Thomas Neumann , Inge Ott , Kristina Schmidt , Daniel Schwizer , Renate Sekul
IPC分类号： C07K1/22 , C07D405/04 , C07D409/04 , C07D231/14 , C07D231/56 , C07D213/82 , C07D403/04 , C07D209/42 , C07D261/20 , C07D307/87 , C07D217/26 , C07D513/04 , C07D471/04 , C07D417/04 , C07D413/04 , C07D235/24 , C07D487/04 , C07D261/18 , C07D271/06 , C07D277/68 , C07D277/56 , C08B37/00
CPC分类号： C07K1/22 , B01D15/3804 , B01J20/289 , B01J20/3251 , B01J20/3253 , B01J20/3255 , C07D209/42 , C07D213/82 , C07D217/26 , C07D231/14 , C07D231/56 , C07D235/24 , C07D261/18 , C07D261/20 , C07D271/06 , C07D277/46 , C07D277/56 , C07D277/68 , C07D277/82 , C07D307/87 , C07D403/04 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/04 , C07D519/00 , C07K16/00 , C08B37/0039
摘要： The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) wherein Sp is a spacer group; v is 0 or 1; Am is an amide group —NR1—C(O)—, and wherein either NR1 is attached to Ar1 and —C(O)— is attached to Ar2, or —C(O)— is attached to Ar1 and NR1 is attached to Ar2; and R1 is hydrogen or C1 to C4 alkyl, preferably hydrogen or methyl; and more preferably hydrogen; Ar1 is a divalent 5- or 6-membered substituted or unsubstituted aromatic ring; Ar2 is 5- or 6-membered heterocyclic aromatic ring which is (a) attached to a further 5- or 6-membered aromatic ring via a single bond; or (b) fused to a further 5- or 6-membered aromatic ring as part of a multicyclic ring system; or (c) attached to at least one substituent selected from C1 to C4 alkyl; C2 to C4 alkenyl; C2 to C4 alkynyl; a halogen; C1 to C4 haloalkyl; hydroxyl-substituted C1 to C4 alkyl; C1 to C4 alkoxy; hydroxyl-substituted C1 to C4 alkoxy; C1 to C4 alkylamino; C1 to C4 alkylthio; and combinations thereof.
摘要翻译：本发明涉及用于亲和纯化抗体或抗体片段的配体取代基质，其包含载体材料和至少一种与载体材料共价结合的配体，所述配体由式（I ）其中Sp为间隔基; v为0或1; Am是酰胺基-NR1-C（O） - ，并且其中NR1与Ar1连接，-C（O） - 连接到Ar2上，或-C（O） - 连接到Ar1上，并且NR1连接到 Ar2; 并且R 1是氢或C 1至C 4烷基，优选氢或甲基; 更优选氢; Ar1是二价的5-或6-元取代或未取代的芳环; Ar 2是5-或6-元杂环芳环，其是（a）通过单键与另一个5-或6-元芳环相连; 或（b）作为多环系统的一部分与另一个5-或6-元芳环稠合; 或（c）连接至至少一个选自C 1至C 4烷基的取代基; C2至C4烯基; C2至C4炔基; 卤素 C1至C4卤代烷基; 羟基取代的C1至C4烷基; C1至C4烷氧基; 羟基取代的C1至C4烷氧基; C1至C4烷基氨基; C1〜C4烷硫基; 及其组合。

2. 发明授权

US10729778B2 Carrier-linked treprostinil prodrugs 有权
公开(公告)号：US10729778B2
公开(公告)日：2020-08-04
申请号：US15418180
申请日：2017-01-27
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K47/60 , A61K47/64
摘要： Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).

3. 发明授权

US06268516B1 Cationic amphiphilic lipids for liposomal gene transfer 失效
标题翻译：阳离子两亲脂质用于脂质体基因转移
公开(公告)号：US06268516B1
公开(公告)日：2001-07-31
申请号：US09230842
申请日：1999-03-30
申请人： Manfred Schneider , Oliver Keil , Regina Reszka , Detlef Groth
发明人： Manfred Schneider , Oliver Keil , Regina Reszka , Detlef Groth
IPC分类号： C07C22900
CPC分类号： A61K48/00 , A61K9/1272 , C07C237/12 , C07C271/20 , C07C279/14 , C07J41/0055 , C07J41/0072 , C12N15/88
摘要： This invention relates to the synthesis of novel cationic, amphiphilic lipids and their application as gene transfer vehicles in vitro and in vivo. For this a series of different lipids (diglycerides, steroids) were synthesized by modification with variable cationic molecules (amino acids, biogenic amines). Compounds of this kind are, due to their capability of producing complexes with polynucleotides (DNA, RNA, Antisense oligonucleotides, ribozymes etc) suitable as vectors for gene transfer (transfection).
摘要翻译：本发明涉及新型阳离子，两亲性脂质的合成及其在体外和体内作为基因转运载体的应用。为此，通过用可变阳离子分子（氨基酸，生物胺）进行修饰来合成一系列不同的脂质（甘油二酯，类固醇）。由于它们与适合作为基因转移（转染）载体的多核苷酸（DNA，RNA，反义寡核苷酸，核酶等）产生复合物的能力，这类化合物。

4. 发明申请

US20100062967A1 COATED LIPID COMPLEXES AND THEIR USE 有权
标题翻译：涂层脂肪复合物及其用途
公开(公告)号：US20100062967A1
公开(公告)日：2010-03-11
申请号：US11722948
申请日：2005-12-27
申请人： Oliver Keil , Jorg Kaufmann
发明人： Oliver Keil , Jorg Kaufmann
IPC分类号： A61K47/48 , A61K47/44 , A61K47/30 , A61K38/02 , A61K31/7088 , A61K31/7105 , C12N5/06
CPC分类号： A61K47/48815 , A61K31/713 , A61K47/543 , A61K47/6911 , A61K48/0033 , Y10S977/907 , Y10T428/2984
摘要： The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.
摘要翻译：本发明涉及包含至少第一种脂质组分，至少第一辅助脂质和在体内条件下可从脂质组合物中除去的屏蔽化合物的脂质组合物。

5. 发明申请

US20090304678A1 Means for Inhibiting the Expression of Protein Kinase 3 有权
公开(公告)号：US20090304678A1
公开(公告)日：2009-12-10
申请号：US12307052
申请日：2007-07-20
申请人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
发明人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
IPC分类号： A61K39/395 , C07H21/04 , C12N5/06 , C12N15/63 , C12N5/10 , A61K31/711
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/321 , C12N2310/3521
摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO:1 (NM_013355), or part thereof, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 482 to 500 of SEQ ID NO:1 (SEQ ID NO:2); from nucleotide positions 1555 to 1573 of SEQ ID NO:1 (SEQ ID NO:4); from nucleotide positions 1556 to 1574 of SEQ ID NO:1 (SEQ ID NO:6); from nucleotide positions 1559 to 1577 of SEQ ID NO:1 (SEQ ID NO:8); from nucleotide positions 1566 to 1584 of SEQ ID NO:1 (SEQ ID NO:10); from nucleotide positions 2094 to 2112 of SEQ ID NO:1 (SEQ ID NO:12); from nucleotide positions 2102 to 2120 of SEQ ID NO:1 (SEQ ID NO:14); from nucleotide positions 2286 to 2304 of SEQ ID NO:1 (SEQ ID NO:16); from nucleotide positions 2761 to 2779 of SEQ ID NO:1 (SEQ ID NO:18); from nucleotide positions 2763 to 2781 of SEQ ID NO:1 (SEQ ID NO:20); from nucleotide positions 2764 to 2782 of SEQ ID NO:1 (SEQ ID NO:22); from nucleotide positions 2843 to 2861 of SEQ ID NO:1 (SEQ ID NO:24); from nucleotide positions 2844 to 2862 of SEQ ID NO:1 (SEQ ID NO:26); or from nucleotide positions 2846 to 2864 of SEQ ID NO:1 (SEQ ID NO:28), preferably the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1555 to 1573 of SEQ ID NO:1 (SEQ ID NO:4); from nucleotide positions 1556 to 1574 of SEQ ID NO:1 (SEQ ID NO:6); from nucleotide positions 1559 to 1577 of SEQ ID NO:1 (SEQ ID NO:8); from nucleotide positions 1566 to 1584 of SEQ ID NO:1 (SEQ ID NO:10); from nucleotide positions 2094 to 2112 of SEQ ID NO:1 (SEQ ID NO:12); or from nucleotide positions 2286 to 2304 of SEQ ID NO:1 (SEQ ID NO:16), whereby preferably the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence.

6. 发明授权

US08232256B2 Means for inhibiting the expression of protein kinase 3 有权
标题翻译：抑制蛋白激酶3表达的方法
公开(公告)号：US08232256B2
公开(公告)日：2012-07-31
申请号：US12307052
申请日：2007-07-20
申请人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
发明人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
IPC分类号： C12N15/11 , C12N5/00 , C07H21/02 , C07H21/04 , C12Q1/68 , C12P19/34
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/321 , C12N2310/3521
摘要： The present invention is related to a nucleic acid molecule and uses thereof. The nucleic acid molecule comprises a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO:1 (NM_013355).
摘要翻译：本发明涉及核酸分子及其用途。所述核酸分子包含双链结构，由此所述双链结构包含第一链和第二链，其中所述第一链包含连续核苷酸的第一段，并且所述第一段与靶核酸至少部分互补并且其中所述第二链包含连续核苷酸的第二段，并且所述第二段与所述第一区段至少部分互补，其中所述第一区段包含核酸序列，所述核酸序列与所述第一区段的核苷酸核心序列至少部分互补根据SEQ ID NO：1的核酸序列（NM_013355）。

7. 发明授权

US08017804B2 Lipids, lipid complexes and use thereof 有权
标题翻译：脂质，脂质复合物及其用途
公开(公告)号：US08017804B2
公开(公告)日：2011-09-13
申请号：US11579700
申请日：2005-05-06
申请人： Oliver Keil , Jörg Kaufmann
发明人： Oliver Keil , Jörg Kaufmann
IPC分类号： C07C233/05
CPC分类号： C07C209/50 , A61K9/1271 , A61K9/1272 , A61K31/713 , A61K47/183 , A61K47/186 , A61K47/24 , A61K47/543 , A61K47/544 , A61K47/6911 , C07C231/02 , C07C279/14 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/321 , C12N2320/32 , C12N2310/3521
摘要： The present invention is related to a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and YÉ is a pharmaceutically acceptable anion.
摘要翻译：本发明涉及式（I）化合物，其中R 1和R 2各自独立地选自烷基; n是1到4之间的整数; R3是选自根据式（II）的赖氨酰，鸟氨酰基，2,4-二氨基丁酰基，组氨酰和酰基部分的酰基，其中m是1至3的任何整数，YÉ是药学上可接受的阴离子。

8. 发明申请

US20090074852A1 LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM 审中-公开
标题翻译：用于特异性输送到血管内皮的LIPOPLEX制剂
公开(公告)号：US20090074852A1
公开(公告)日：2009-03-19
申请号：US12297611
申请日：2007-04-20
申请人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
发明人： Jorg Kaufmann , Oliver Keil , Ansgar Santel
IPC分类号： A61K9/127 , A61K31/16 , A61K31/7088 , C07H21/02 , C12N5/02 , C12Q1/02 , A61P35/04
CPC分类号： A61K9/1271 , A61K9/1272 , A61K47/6911 , A61K48/00
摘要： The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, preferably about 250-350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 mm.
摘要翻译：本发明涉及含有载体和/或含有载体的脂质组合物，其包含至少第一种脂质组分，至少第一辅助脂质和在体内条件下任选地从脂质组合物中除去的屏蔽化合物，由此含脂质组合物的载体具有约50至600 mosmol / kg，优选约250-350 mosmol / kg，更优选约280至320 mosmol / kg的渗透压，和/或其中由第一脂质组分和/ 或载体中辅助脂质和屏蔽化合物中的一种或两种具有约20至200nm，优选约30至100nm，更优选约40至80mm的粒度。

9. 发明授权

US09561287B2 Carrier-linked treprostinil prodrugs 有权
标题翻译：载体连接的曲前列腺素前药
公开(公告)号：US09561287B2
公开(公告)日：2017-02-07
申请号：US14238437
申请日：2012-08-10
申请人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Ulrich Hersel , Harald Rau , Torben Lessmann , Nicola Bisek , Guillaume Maitro , Kennett Sprogøe , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K47/48
CPC分类号： A61K47/48253 , A61K47/60 , A61K47/641 , A61K47/645
摘要： The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).
摘要翻译：本发明涉及包含共价曲前列腺素载体缀合物的前药或其药学上可接受的盐以及包含所述化合物的药物组合物。这些化合物可以用作药物，特别是可以通过曲前列素治疗的疾病或病症，例如肺动脉高压（PAH）。

10. 发明申请

US20140303245A1 Sustained Release Composition of Prostacyclin 有权
标题翻译：前列环素缓释组合物
公开(公告)号：US20140303245A1
公开(公告)日：2014-10-09
申请号：US14238147
申请日：2012-08-10
申请人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
发明人： Kennett Sprogøe , Harald Rau , Ulrich Hersel , Thomas Wegge , Oliver Keil , Joachim Zettler
IPC分类号： A61K31/5585 , A61K47/48
CPC分类号： A61K31/5585 , A61K31/557 , A61K47/60
摘要： The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.
摘要翻译：本发明涉及前列环素的缓释组合物及其用途，特别是用于预防和/或治疗肺动脉高血压。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式